alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 120 studies by Jack CR marked Peer-reviewed (page 4 of 5) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 120 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-11-05

Major imaging biomarkers of Alzheimer's disease include amyloid deposition [imaged with [(11)C]Pittsburgh compound B (PiB) PET], altered glucose metabolism (imaged with [(18)F]fluro-deoxyglucose PET), and structural atrophy (imaged by MRI). 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Frontiers in neuroscience 2012-08-06

We implemented least absolute shrinkage and selection operator (LASSO) regression to evaluate gene effects in genome-wide association studies (GWAS) of brain images, using an MRI-derived temporal lobe volume measure from 729 subjects scanned as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI). 3 key findings →

Participants: 729 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease Endophenotypes

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neurology. Genetics 2024-01-10

We found that ML-PRS approaches improved upon standard PRS for prediction of AD endophenotypes, partly related to improved accounting for nonlinear effects of genetic susceptibility alleles. 3 key findings →

Participants: 1,791 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Suspected non-Alzheimer disease pathophysiology--concept and controversy

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Nature reviews. Neurology 2016-01-18

Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegeneration are abnormal. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neurology 2007-09-26

The regions of loss observed in subjects with amnestic mild cognitive impairment (aMCI) who progressed to Alzheimer disease (AD) within 18 months of the MRI are typical of subjects with AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Frontiers in neuroinformatics 2019-02-19

Brain imaging with diffusion-weighted MRI (dMRI) is sensitive to microstructural white matter (WM) changes associated with brain aging and neurodegeneration. 4 key findings →

Participants: 317 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Archives of neurology 2005-06-01

The APOE*E4 genotype status appears to have a greater deleterious effect on gross hippocampal pathology and memory performance in women than in men. 4 key findings →

Participants: 193 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Archives of neurology 2010-11-01

White matter hyperintensity volume predicts 1-year cognitive decline in a relatively healthy convenience sample that was similar to clinical trial samples, and therefore should be considered as a covariate of interest at baseline and longitudinally in future AD treatment trials. 3 key findings →

Participants: 804 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain : a journal of neurology 2015-09-30

We recently demonstrated that the frequencies of biomarker groups defined by the presence or absence of both amyloidosis (A+) and neurodegeneration (N+) changed dramatically by age in cognitively non-impaired subjects. 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2012-11-01

In this cross-sectional study, we found an association between Aβ brain burden measured in vivo and DBP and cortisol, indicating a possible link between these CVRF and Aβ burden measured by PiB-PET. 5 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurology 2012-05-02

Of the 296 initially normal subjects, 31 (10%) progressed to a diagnosis of mild cognitive impairment (MCI) or dementia (27 amnestic MCI, 2 nonamnestic MCI, and 2 non-AD dementias) within 1 year. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2010-06-11

MRI research examining structural brain atrophy in Alzheimer's disease (AD) generally focuses on medial temporal and cortical structures, but amyloid and tau deposits also accumulate in the caudate. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Lancet. Neurology 2014-09-04

As preclinical Alzheimer's disease becomes a target for therapeutic intervention, the overlap between imaging abnormalities associated with typical ageing and those associated with Alzheimer's disease needs to be recognised. 4 key findings →

Participants: 985 Evidence: low

Full summary, score breakdown and related studies → Original source

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-06-27

The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2014-03-11

In region-of-interest (ROI) analyses, we found modest but statistically significant declines in FDG ratio in most cortical and subcortical regions as a function of age. 4 key findings →

Participants: 806 Evidence: low

Full summary, score breakdown and related studies → Original source

Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer's Disease Neuroimaging Initiative

✓ Peer-reviewed alzhub usefulness score 47 out of 100. AJNR. American journal of neuroradiology 2015-01-22

Prior MR imaging studies, primarily at 1.5T, established hippocampal atrophy as a biomarker for Alzheimer disease. 3T MR imaging offers a higher contrast and signal-to-noise ratio, yet distortions and intensity uniformity are harder to control. 4 key findings →

Participants: 166 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurology 2000-05-01

Despite the theoretical rationale for the superiority of entorhinal measurements in early AD, the authors found MRI measurements of the hippocampus and entorhinal cortex were approximately equivalent at intergroup discrimination. 2 key findings →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source

Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Brain communications 2021-02-02

Our results confirm plasma β-amyloid 42 /β-amyloid 40 as a robust biomarker of brain β-amyloid-positivity (area under curve, 0.80-0.87). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging 2010-12-14

The current study tested the accuracy of primary MRI and cerebrospinal fluid (CSF) biomarker candidates and neuropsychological tests for predicting the conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia. 1 key finding →

Participants: 81 Evidence: low

Full summary, score breakdown and related studies → Original source

Brain injury biomarkers are not dependent on β-amyloid in normal elderly

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Annals of neurology 2013-02-19

Cognitively normal persons with brain injury biomarker abnormalities, with or without abnormal levels of β-amyloid, were indistinguishable on a variety of imaging markers, clinical features, and risk factors. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events